top of page

New medicine supply notices




Due to a shipping delay and increased demand, Link (the supplier) has limited supply of this product. Other presentations of alfacalcidol remain available.



Biscodyl-AFT is listed from 1 February. It will not be available to order until later in February. There is still ample stock of Bisacodyl Viatris, it will not be delisted until 1 July 2026.


Calcium Resonium powder (Pharmacode: 201510)


Due to delays at the manufacturer, Calcium Resonium powder will be unavailable between late February and May 2026. An alternative will be funded from 1 February. It is not Medsafe approved.



Supply has been limited because of an increase in demand and the long lead time needed to make more of this medicine. More stock has arrived this week. However, as it has to be kept in a fridge, it may take another 2 or more weeks to reach pharmacies.


Molaxole: New packaging (Pharmacodes: Old packaging 2519887 | New packaging 2718332)


The packaging for Molaxole will start changing in February. The stock with the new packaging will have a new Pharmacode. Details and a patient flyer on the website.



Stock of this product is low. An alternative is listed from 1 February 2026. The alternative is not Medsafe approved.



Due to a high demand and delivery delays, the supplier expects to run out of olopatadine eye drops before the next shipment arrives in mid-February. There is no direct alternative, people will need to talk to their prescribers.


Updated medicine supply notices



  • Concerta: 27 mg out of stock, all other strengths available

  • Ritalin: All strengths available

  • Rubifen: All strengths available

  • Sandoz XR: All strengths available

  • Teva: All strengths available.



The 50g ointment pack (Pharmacode: 2395746) is back in stock but the 50 g cream (Pharmacode: 2395738) and 15 g ointment (Pharmacode: 218383) have gone out of stock.



  • Fortijuce | Orange (Pharmacode: 2224534)

  • Fortini Multi Fibre | Unflavoured (Pharmacode: 2702819) and Chocolate (Pharmacode: 2702797)

  • GMPro Ultra Lemonade | Pharmacode: 2657201

  • MSUD Lophlex LQ 20 | Pharmacodes: 2683016 and 2711451

  • Nutrini peptisorb | Pharmacode: 2702460

  • Nutrini Peptisorb Energy | Pharmacode: 2702479

  • PKU Lophlex powder | Pharmacode: 2642999

  • Renilon 7.5 | Caramel 2439387



The supplier has run out of all three strengths of the Max Health brand of octreotide ampoules. The Omega brand vials are available to order in their place. The Omega brand is supplied under Section 29 of the Medicine Act.


Oxytocin (inj 10 iu per ml) (Pharmacode: 2577046) A shipment of the New Zealand product has arrived. It may take another 2 to 3 weeks to reach pharmacies around New Zealand.



Two more alternative brands from Germany and Italy will be listed from 1 February. This stock is already available in New Zealand. Stock of the Somex S29 brand (Pharmacode: 2628295 funded 1 January) should be available in the last week of January.


Resolved issues


Note: Supply issues are marked as resolved when the supplier has product available. It can take another 1 to 2 weeks for stock to reach pharmacies around the motu.

Unapproved medicines and supply issues

The Medicines Act was changed in 2025 to allow any authorised prescriber to prescribe unapproved medicines when they were being funded to cover a supply issue identified by Pharmac.


We have added a tag to our medicine supply notice to indicate where an unapproved medicine has been funded to cover the supply issue of a registered medicine (Section 29A of the Medicines Act applies).


Tender brand changes


Celecoxib


1 February 2026

  • Celecoxib Pfizer 100 mg, supplied by Aspen, delisted from the Schedule.

  • Celebrex 100 mg, supplied by Aspen, continues to be listed.

  • Celostea 200 mg, supplied by Viatris, listed on the Pharmaceutical from 1 February 2026.


1 July 2026


  • Celecoxib Pfizer 200 mg, supplied by Aspen, delisted from the Schedule.


Compound electrolytes with glucose [dextrose] solution


The brand is changing from Hydralyte - Lemonade to Pedialyte.


1 February 2026


  • Pedialyte, supplied by Abbott, is listed in the Schedule


1 July 2026 


  • Hydralyte - Lemonade, supplied by Care Pharmaceuticals, delisted from the Schedule


Pedialyte will have Principal Supply Status in the Community Pharmaceutical and in Health NZ hospitals from 1 July 2026 until 30 June 2028.


Recent decisions and open consultations



Proposal to fund ferric derisomaltose in hospitals (Consultation closes: 30 January) 


Monthly updates


bottom of page